Cancer Survivor Cardiomyopathy Detection (CASCADE)

Mayo Clinic

Status: Active, not recruiting

Conditions: Cardiovascular Diseases; Cancer

Treatments: Diagnostic Test: Echocardiogram; Diagnostic Test: Electrocardiogram; Diagnostic Test: NT-pro-BNP

Study type: Observational

Funder types: Other

Identifiers

NCT05201014

CASCADE

21-006790

NCI-2022-05920 (Registry Identifier)

Details and patient eligibility

About

The purpose of this study is to improve the cardiovascular care of adult cancer survivors. The goal is to obtain the data necessary to plan and develop a nation-wide network of a screening program that can help provide cost-effective and long-term monitoring.

Full description

The primary objective of this study is to define the diagnostic performance and optimal cutoffs of AI-ECG and NT-pro-BNP for the detection of left ventricular dysfunction [LVD, defined as a left ventricular ejection fraction (LVEF) <50%] in cancer patients at 1 year after completion of anthracycline-based chemotherapy.

Enrollment: 112 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ≥18 years of age prior to enrollment and anthracycline start date
• Diagnosis of breast cancer, lymphoma, or sarcoma with either planned or at 1 year after completion of anthracycline therapy, including patients from 6-12 months and greater than 1 year post-anthracycline exposure.
• Patients with a history of persistent atrial fibrillation (afib) that are not in afib remission. Include if the most recent ECG does not show afib. Atrial flutter treated the same

Exclusion criteria

• LVEF <50% or prior confirmed history of cardiomyopathy, heart failure, left bundle branch block, or paced rhythm
• Patients with a history of persistent atrial fibrillation (afib) that are not in afib remission. Include if the most recent ECG does not show afib. Atrial flutter treated the same.
• Individuals with pacemakers, defibrillators, or other implanted electronic devices
• Inability/unwillingness of individual to give written informed consent

Trial design

112 participants in 2 patient groups

1 year follow-up

Description:

patients who were treated in the year before and are now returning for their 1-year follow-up.

Treatment:

Diagnostic Test: NT-pro-BNP

Diagnostic Test: Echocardiogram

Diagnostic Test: Electrocardiogram

Prior to anthracycline-based therapy

Description:

patients presenting before the start of anthracycline-based therapy, then to be followed thereafter for 1 year and thereby contributing to the pool of patients with 1-year post-anthracycline assessment.

Treatment:

Diagnostic Test: NT-pro-BNP

Diagnostic Test: Echocardiogram

Diagnostic Test: Electrocardiogram